Articles by Jill Wechsler - Pharmaceutical Executive


Articles by Jill Wechsler

Fleshing Out FDASIA

Aug 1, 2012

Medical apps, e-submissions, counterfeit drugs, and imports tucked into fairly "clean" user-fee renewal legislation.

Who Will Pay for New Drugs?

Jul 1, 2012

Comparative research documenting value and affordability is key to obtaining coverage for high-cost therapies. Jill Wechsler reports.

Innovation and Collaboration

Jun 1, 2012

A rash of "pro-innovative" approaches for testing and regulating medical products offer ways to speed more new products to market.

Comparative Effectiveness Research: Challenges for Pharma

May 9, 2012

Switching Rx drugs to OTC and adding comparative data could broaden access to treatment, writes Jill Wechsler.

Shortages and Sunshine

Apr 1, 2012

Disclosure rules the day, as industry confronts demands to report supply problems, results of clinical trials, and payment to doctors.

When Talk is Not So Cheap

Mar 1, 2012

FDA and industry are pushing user fees, while they struggle with curbs on communications.

FDA Unveils Guidance for Biosimilar Development

Feb 10, 2012

After months of anticipation, FDA finally issued guidances last month that outlines its recommendations for developing and approving biosimilar therapies.

Costs and Benefits of Health Reform

Feb 1, 2012

Will expanded markets and ACOs offset higher rebates, added fees, and closer scrutiny of marketing and prices?

New Year, New Issues

Jan 1, 2012

Look for action in 2012 on drug access, shortages, innovation, and transparency.


Click here